Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer's and Parkinson's disease brains.

Acta Neuropathol

Department of Neurology, USC Neuromuscular Center, Good Samaritan Hospital, University of Southern California Keck School of Medicine, 637 South Lucas Avenue, Los Angeles, CA 90017-1912, USA.

Published: December 2008

Sporadic inclusion-body myositis (s-IBM), the most common muscle disease of older persons, is of unknown cause and lacks successful treatment. Here we summarize diagnostic criteria and discuss our current understanding of the steps in the pathogenic cascade. While it is agreed that both degeneration and mononuclear-cell inflammation are components of the s-IBM pathology, how each relates to the pathogenesis remains unsettled. We suggest that the intra-muscle-fiber degenerative component plays the primary role, leading to muscle-fiber destruction and clinical weakness, since anti-inflammatory treatments are not of sustained benefit. We discuss possible treatment strategies aimed toward ameliorating a degenerative component, for example, lithium and resveratrol. Also discussed are the intriguing phenotypic similarities between s-IBM muscle fibers and the brains of Alzheimer and Parkinson's diseases, the most common neurodegenerative diseases associated with aging. Similarities include, in the respective tissues, cellular aging, mitochondrial abnormalities, oxidative and endoplasmic-reticulum stresses, proteasome inhibition and multiprotein aggregates.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2635944PMC
http://dx.doi.org/10.1007/s00401-008-0449-0DOI Listing

Publication Analysis

Top Keywords

inclusion-body myositis
8
degenerative component
8
myositis muscle-fiber
4
muscle-fiber molecular
4
molecular pathology
4
pathology pathogenic
4
pathogenic significance
4
significance similarity
4
similarity alzheimer's
4
alzheimer's parkinson's
4

Similar Publications

Background: Inclusion body myositis (IBM) is the most prevalent muscle disease in adults for which no current treatment exists. The pathogenesis of IBM remains poorly defined. In this study, we aimed to explore the interplay between inflammation and mitochondrial dysfunction in IBM.

View Article and Find Full Text PDF

Inclusion Body Myositis: A case report on navigating diagnostic challenges.

Sultan Qaboos Univ Med J

November 2024

Internal Medicine Residency Program, Oman Medical Specialty Board, Muscat, Oman.

Article Synopsis
  • * A 72-year-old woman was diagnosed with IBM after experiencing progressive weakness in her lower limbs, with a muscle biopsy being the gold standard for diagnosis.
  • * The patient received a combination of treatments, resulting in moderate improvement, highlighting the importance of accurate diagnosis and a collaborative approach in managing IBM.
View Article and Find Full Text PDF

Clinical Significance of Abnormal Serum LGALS3BP Expression in Patients with Idiopathic Inflammatory Myopathies.

J Inflamm Res

November 2024

Department of Clinical Laboratory, the First Affiliated Hospital of Guangxi Medical University, Key Laboratory of Clinical Laboratory Medicine of Guangxi Department of Education, Nanning, Guangxi, 530021, People's Republic of China.

Article Synopsis
  • - The study investigates the role of LGALS3BP as a potential biomarker to differentiate between four subtypes of idiopathic inflammatory myopathies (IIM): dermatomyositis (DM), anti-synthetase syndrome (ASS), immune-mediated necrotizing myopathy (IMNM), and sporadic inclusion body myositis (sIBM), alongside healthy controls (HCs).
  • - Using bioinformatics and enzyme-linked immunosorbent assay (ELISA), the researchers found that serum LGALS3BP levels varied significantly across the IIM subtypes and were linked to clinical features and inflammatory markers, particularly indicating a higher prevalence of interstitial lung disease (ILD) in patients with elevated levels.
  • - The
View Article and Find Full Text PDF
Article Synopsis
  • TDP-43 is an RNA binding protein that forms aggregates in the central nervous system and is notably present in certain neurodegenerative diseases and inclusion body myopathy, a type of muscle disease.
  • Researchers developed a mouse model that shows muscle weakness associated with TDP-43 accumulation, which indicates a prion-like spread of the protein possibly affecting muscle tissues.
  • Human muscle biopsies from patients with various conditions, especially inclusion body myositis (IBM), contain TDP-43 aggregate seeds, suggesting a unique pathogenic role for TDP-43 in muscle diseases that wasn't fully recognized before.
View Article and Find Full Text PDF

Autoantibodies against a subunit of mitochondrial respiratory chain complex I in inclusion body myositis.

J Autoimmun

December 2024

Karolinska Institutet, Division of Rheumatology, Department of Medicine, Solna, Stockholm, Sweden; Department of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden; Karolinska Institutet, Center for Molecular Medicine, Stockholm, Sweden.

Background: Autoantibodies are found in up to 80 % of patients with idiopathic inflammatory myopathies (IIM) and are associated with distinct clinical phenotypes. Autoantibodies targeting cytosolic 5'-nucleotidase 1A (anti-NT5C1A) are currently the only known serum biomarker for the subgroup inclusion body myositis (IBM), although detected even in other autoimmune diseases. The aim of the study was to identify new autoimmune targets in IIM.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!